Resource Library

The U.S. Supreme Court’s decision overturning Chevron deference. This articles discusses the ruling, which calls for courts to reassume their role as interpreters of the law.

This article provides an overview of the False Claims Act (FCA).

In this article you will learn about, the types of FCA cases in health care, damages and penalties under the FCA, and cooperation considerations for companies and individuals under government scrutiny.

US Attorney General Pam Bondi has renewed the prior Trump administration’s prohibition on the use of sub-regulatory guidance, potentially altering the landscape for False Claims Act cases pursued during the second Trump administration.

This is sample tool helping organizations assess whether a security incident involving personal information would require notification under the HIPAA breach notification rule (under the US Health Insurance Portability and Accountability Act).

This guide provides corporate counsel and international practitioners with comprehensive jurisdiction-by-jurisdiction guidance to digital health laws and regulations around the world.

This guide provides a compilation of insights from legal practitioners to assist in the identification and understanding of the laws and regulations that impact the drug and medical device industry.

Patented medicine regulations in Canada can be complex and the review process is fast-paced. In this Top Ten, in-house counsel will learn the essential points of how to prepare for the "Regulations" review. Editor's note: This article was updated to reflect recent developments; a prior version of this article was published on August 6, 2020.

People around the world continue to grapple with the COVID-19 pandemic, the most extreme public health emergency in a century. This Top Ten discusses the public health law framework in the United States and summarizes some recent developments in the law arising from the COVID-19 pandemic.

The Personalized Medicine Coalition (PMC) recently released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022 (“Report”). As summarized in the Report, 2022 milestones include progress in diagnostics, therapeutics and new treatment modalities that are covered in this resource from Foley and Lardner LLP.

With the pandemic, there came a digital health explosion, with companies working swiftly to bring new technologies to light that would pave the way forward in telehealth and other critical areas. We saw an incredible interest in this space then, but what is the state of digital health now? This resource from Foley & Lardner LLP looks at data from public and private financing markets in the digital health space in 2022, and look forward to what to expect in 2023.